Coherus BioSciences Stock (NASDAQ: CHRS) stock price, news, charts, stock research, profile.
Day Range8.160 - 8.450 | 52 Wk Range5.581 - 14.110 | Open / Close8.410 / 8.420 | Float / Outstanding61.490M / 77.778M |
Vol / Avg.588.065K / 1.270M | Mkt Cap654.890M | P/E- | 50d Avg. Price7.990 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float61.490M | EPS-3.590 |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-05-04 | ||||||
REV |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.690 | (EXPECTED) 2023-02-21 | |||||
REV | 48.380M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Coherus BioSciences (NASDAQ: CHRS) through any online brokerage.
Other companies in Coherus BioSciences’s space includes: ARS Pharmaceuticals (NASDAQ:SPRY), 4D Molecular Therapeutics (NASDAQ:FDMT), bluebird bio (NASDAQ:BLUE), Immatics (NASDAQ:IMTX) and Fate Therapeutics (NASDAQ:FATE).
The latest price target for Coherus BioSciences (NASDAQ: CHRS) was reported by Mizuho on Wednesday, November 16, 2022. The analyst firm set a price target for 21.00 expecting CHRS to rise to within 12 months (a possible 149.41% upside). 7 analyst firms have reported ratings in the last year.
The stock price for Coherus BioSciences (NASDAQ: CHRS) is $8.42 last updated February 7, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Coherus BioSciences.
Coherus BioSciences’s Q1 earnings are confirmed for Thursday, May 4, 2023.
There is no upcoming split for Coherus BioSciences.
Coherus BioSciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Coherus BioSciences Stock (NASDAQ: CHRS) stock price, news, charts, stock research, profile.
Day Range8.160 - 8.450 | 52 Wk Range5.581 - 14.110 | Open / Close8.410 / 8.420 | Float / Outstanding61.490M / 77.778M |
Vol / Avg.588.065K / 1.270M | Mkt Cap654.890M | P/E- | 50d Avg. Price7.990 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float61.490M | EPS-3.590 |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-05-04 | ||||||
REV |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.690 | (EXPECTED) 2023-02-21 | |||||
REV | 48.380M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Coherus BioSciences (NASDAQ: CHRS) through any online brokerage.
Other companies in Coherus BioSciences’s space includes: ARS Pharmaceuticals (NASDAQ:SPRY), 4D Molecular Therapeutics (NASDAQ:FDMT), bluebird bio (NASDAQ:BLUE), Immatics (NASDAQ:IMTX) and Fate Therapeutics (NASDAQ:FATE).
The latest price target for Coherus BioSciences (NASDAQ: CHRS) was reported by Mizuho on Wednesday, November 16, 2022. The analyst firm set a price target for 21.00 expecting CHRS to rise to within 12 months (a possible 149.41% upside). 7 analyst firms have reported ratings in the last year.
The stock price for Coherus BioSciences (NASDAQ: CHRS) is $8.42 last updated February 7, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Coherus BioSciences.
Coherus BioSciences’s Q1 earnings are confirmed for Thursday, May 4, 2023.
There is no upcoming split for Coherus BioSciences.
Coherus BioSciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Coherus BioSciences Stock (NASDAQ: CHRS) stock price, news, charts, stock research, profile.
Day Range8.160 - 8.450 | 52 Wk Range5.581 - 14.110 | Open / Close8.410 / 8.420 | Float / Outstanding61.490M / 77.778M |
Vol / Avg.588.065K / 1.270M | Mkt Cap654.890M | P/E- | 50d Avg. Price7.990 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float61.490M | EPS-3.590 |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-05-04 | ||||||
REV |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.690 | (EXPECTED) 2023-02-21 | |||||
REV | 48.380M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Coherus BioSciences (NASDAQ: CHRS) through any online brokerage.
Other companies in Coherus BioSciences’s space includes: ARS Pharmaceuticals (NASDAQ:SPRY), 4D Molecular Therapeutics (NASDAQ:FDMT), bluebird bio (NASDAQ:BLUE), Immatics (NASDAQ:IMTX) and Fate Therapeutics (NASDAQ:FATE).
The latest price target for Coherus BioSciences (NASDAQ: CHRS) was reported by Mizuho on Wednesday, November 16, 2022. The analyst firm set a price target for 21.00 expecting CHRS to rise to within 12 months (a possible 149.41% upside). 7 analyst firms have reported ratings in the last year.
The stock price for Coherus BioSciences (NASDAQ: CHRS) is $8.42 last updated February 7, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Coherus BioSciences.
Coherus BioSciences’s Q1 earnings are confirmed for Thursday, May 4, 2023.
There is no upcoming split for Coherus BioSciences.
Coherus BioSciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Coherus BioSciences Stock (NASDAQ: CHRS) stock price, news, charts, stock research, profile.
Day Range8.160 - 8.450 | 52 Wk Range5.581 - 14.110 | Open / Close8.410 / 8.420 | Float / Outstanding61.490M / 77.778M |
Vol / Avg.588.065K / 1.270M | Mkt Cap654.890M | P/E- | 50d Avg. Price7.990 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float61.490M | EPS-3.590 |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-05-04 | ||||||
REV |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.690 | (EXPECTED) 2023-02-21 | |||||
REV | 48.380M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Coherus BioSciences (NASDAQ: CHRS) through any online brokerage.
Other companies in Coherus BioSciences’s space includes: ARS Pharmaceuticals (NASDAQ:SPRY), 4D Molecular Therapeutics (NASDAQ:FDMT), bluebird bio (NASDAQ:BLUE), Immatics (NASDAQ:IMTX) and Fate Therapeutics (NASDAQ:FATE).
The latest price target for Coherus BioSciences (NASDAQ: CHRS) was reported by Mizuho on Wednesday, November 16, 2022. The analyst firm set a price target for 21.00 expecting CHRS to rise to within 12 months (a possible 149.41% upside). 7 analyst firms have reported ratings in the last year.
The stock price for Coherus BioSciences (NASDAQ: CHRS) is $8.42 last updated February 7, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Coherus BioSciences.
Coherus BioSciences’s Q1 earnings are confirmed for Thursday, May 4, 2023.
There is no upcoming split for Coherus BioSciences.
Coherus BioSciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Coherus BioSciences Stock (NASDAQ: CHRS) stock price, news, charts, stock research, profile.
Day Range8.160 - 8.450 | 52 Wk Range5.581 - 14.110 | Open / Close8.410 / 8.420 | Float / Outstanding61.490M / 77.778M |
Vol / Avg.588.065K / 1.270M | Mkt Cap654.890M | P/E- | 50d Avg. Price7.990 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float61.490M | EPS-3.590 |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-05-04 | ||||||
REV |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.690 | (EXPECTED) 2023-02-21 | |||||
REV | 48.380M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Coherus BioSciences (NASDAQ: CHRS) through any online brokerage.
Other companies in Coherus BioSciences’s space includes: ARS Pharmaceuticals (NASDAQ:SPRY), 4D Molecular Therapeutics (NASDAQ:FDMT), bluebird bio (NASDAQ:BLUE), Immatics (NASDAQ:IMTX) and Fate Therapeutics (NASDAQ:FATE).
The latest price target for Coherus BioSciences (NASDAQ: CHRS) was reported by Mizuho on Wednesday, November 16, 2022. The analyst firm set a price target for 21.00 expecting CHRS to rise to within 12 months (a possible 149.41% upside). 7 analyst firms have reported ratings in the last year.
The stock price for Coherus BioSciences (NASDAQ: CHRS) is $8.42 last updated February 7, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Coherus BioSciences.
Coherus BioSciences’s Q1 earnings are confirmed for Thursday, May 4, 2023.
There is no upcoming split for Coherus BioSciences.
Coherus BioSciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Coherus BioSciences Stock (NASDAQ: CHRS) stock price, news, charts, stock research, profile.
Day Range8.160 - 8.450 | 52 Wk Range5.581 - 14.110 | Open / Close8.410 / 8.420 | Float / Outstanding61.490M / 77.778M |
Vol / Avg.588.065K / 1.270M | Mkt Cap654.890M | P/E- | 50d Avg. Price7.990 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float61.490M | EPS-3.590 |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-05-04 | ||||||
REV |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.690 | (EXPECTED) 2023-02-21 | |||||
REV | 48.380M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Coherus BioSciences (NASDAQ: CHRS) through any online brokerage.
Other companies in Coherus BioSciences’s space includes: ARS Pharmaceuticals (NASDAQ:SPRY), 4D Molecular Therapeutics (NASDAQ:FDMT), bluebird bio (NASDAQ:BLUE), Immatics (NASDAQ:IMTX) and Fate Therapeutics (NASDAQ:FATE).
The latest price target for Coherus BioSciences (NASDAQ: CHRS) was reported by Mizuho on Wednesday, November 16, 2022. The analyst firm set a price target for 21.00 expecting CHRS to rise to within 12 months (a possible 149.41% upside). 7 analyst firms have reported ratings in the last year.
The stock price for Coherus BioSciences (NASDAQ: CHRS) is $8.42 last updated February 7, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Coherus BioSciences.
Coherus BioSciences’s Q1 earnings are confirmed for Thursday, May 4, 2023.
There is no upcoming split for Coherus BioSciences.
Coherus BioSciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Coherus BioSciences Stock (NASDAQ: CHRS) stock price, news, charts, stock research, profile.
Day Range8.160 - 8.450 | 52 Wk Range5.581 - 14.110 | Open / Close8.410 / 8.420 | Float / Outstanding61.490M / 77.778M |
Vol / Avg.588.065K / 1.270M | Mkt Cap654.890M | P/E- | 50d Avg. Price7.990 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float61.490M | EPS-3.590 |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-05-04 | ||||||
REV |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.690 | (EXPECTED) 2023-02-21 | |||||
REV | 48.380M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Coherus BioSciences (NASDAQ: CHRS) through any online brokerage.
Other companies in Coherus BioSciences’s space includes: ARS Pharmaceuticals (NASDAQ:SPRY), 4D Molecular Therapeutics (NASDAQ:FDMT), bluebird bio (NASDAQ:BLUE), Immatics (NASDAQ:IMTX) and Fate Therapeutics (NASDAQ:FATE).
The latest price target for Coherus BioSciences (NASDAQ: CHRS) was reported by Mizuho on Wednesday, November 16, 2022. The analyst firm set a price target for 21.00 expecting CHRS to rise to within 12 months (a possible 149.41% upside). 7 analyst firms have reported ratings in the last year.
The stock price for Coherus BioSciences (NASDAQ: CHRS) is $8.42 last updated February 7, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Coherus BioSciences.
Coherus BioSciences’s Q1 earnings are confirmed for Thursday, May 4, 2023.
There is no upcoming split for Coherus BioSciences.
Coherus BioSciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Coherus BioSciences Stock (NASDAQ: CHRS) stock price, news, charts, stock research, profile.
Day Range8.160 - 8.450 | 52 Wk Range5.581 - 14.110 | Open / Close8.410 / 8.420 | Float / Outstanding61.490M / 77.778M |
Vol / Avg.588.065K / 1.270M | Mkt Cap654.890M | P/E- | 50d Avg. Price7.990 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float61.490M | EPS-3.590 |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-05-04 | ||||||
REV |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.690 | (EXPECTED) 2023-02-21 | |||||
REV | 48.380M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Coherus BioSciences (NASDAQ: CHRS) through any online brokerage.
Other companies in Coherus BioSciences’s space includes: ARS Pharmaceuticals (NASDAQ:SPRY), 4D Molecular Therapeutics (NASDAQ:FDMT), bluebird bio (NASDAQ:BLUE), Immatics (NASDAQ:IMTX) and Fate Therapeutics (NASDAQ:FATE).
The latest price target for Coherus BioSciences (NASDAQ: CHRS) was reported by Mizuho on Wednesday, November 16, 2022. The analyst firm set a price target for 21.00 expecting CHRS to rise to within 12 months (a possible 149.41% upside). 7 analyst firms have reported ratings in the last year.
The stock price for Coherus BioSciences (NASDAQ: CHRS) is $8.42 last updated February 7, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Coherus BioSciences.
Coherus BioSciences’s Q1 earnings are confirmed for Thursday, May 4, 2023.
There is no upcoming split for Coherus BioSciences.
Coherus BioSciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Coherus BioSciences Stock (NASDAQ: CHRS) stock price, news, charts, stock research, profile.
Day Range8.160 - 8.450 | 52 Wk Range5.581 - 14.110 | Open / Close8.410 / 8.420 | Float / Outstanding61.490M / 77.778M |
Vol / Avg.588.065K / 1.270M | Mkt Cap654.890M | P/E- | 50d Avg. Price7.990 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float61.490M | EPS-3.590 |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-05-04 | ||||||
REV |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.690 | (EXPECTED) 2023-02-21 | |||||
REV | 48.380M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Coherus BioSciences (NASDAQ: CHRS) through any online brokerage.
Other companies in Coherus BioSciences’s space includes: ARS Pharmaceuticals (NASDAQ:SPRY), 4D Molecular Therapeutics (NASDAQ:FDMT), bluebird bio (NASDAQ:BLUE), Immatics (NASDAQ:IMTX) and Fate Therapeutics (NASDAQ:FATE).
The latest price target for Coherus BioSciences (NASDAQ: CHRS) was reported by Mizuho on Wednesday, November 16, 2022. The analyst firm set a price target for 21.00 expecting CHRS to rise to within 12 months (a possible 149.41% upside). 7 analyst firms have reported ratings in the last year.
The stock price for Coherus BioSciences (NASDAQ: CHRS) is $8.42 last updated February 7, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Coherus BioSciences.
Coherus BioSciences’s Q1 earnings are confirmed for Thursday, May 4, 2023.
There is no upcoming split for Coherus BioSciences.
Coherus BioSciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.